

Kallo Inc.  
Form 10-Q  
November 14, 2012

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

- QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY  
PERIOD ENDED SEPTEMBER 30, 2012  
OR  
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53183

KALLO INC.  
(Exact name of registrant as specified in its charter)

NEVADA  
(State or other jurisdiction of incorporation or organization)

15 Allstate Parkway, Suite 600  
Markham, Ontario  
Canada L3R 5B4  
(Address of principal executive offices, including zip code.)

(416) 246-9997  
(Registrant's telephone number, including area code)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES  NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (SS 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer,"

Edgar Filing: Kallo Inc. - Form 10-Q

and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	<input type="radio"/>	Accelerated Filer	<input type="radio"/>
Non-accelerated Filer	<input type="radio"/>	Smaller Reporting Company	<input checked="" type="radio"/>

(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES  NO

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicated the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 274,089,203 as of November 10, 2012.

---

---

---

TABLE OF CONTENTS

	PAGE
<b>PART I</b>	
Item 1. Financial Statements	3
Unaudited Condensed Consolidated Balance Sheets	4
Unaudited Condensed Consolidated Statements Of Operations and Comprehensive Loss	5
Unaudited Condensed Consolidated Statements Of Changes In Stockholders' Equity (Deficiency)	6
Unaudited Condensed Consolidated Statements Of Cash Flows	7
Notes to Unaudited Condensed Consolidated Financial Statements	8
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3. Quantitative and Qualitative Disclosures about Market Risk	18
Item 4. Controls and Procedures	18
<b>PART II</b>	
Item 1. Legal Proceedings.	18
Item 1A. Risk Factors	18
Item 6. Exhibits	18
Signatures	21
Exhibit Index	22



## PART I – FINANCIAL INFORMATION

## ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Condensed Consolidated Balance Sheets

	September 30, 2012	December 31, 2011
<b>ASSETS</b>		
Current Assets:	(unaudited)	
Cash	\$248,178	\$15,821
Prepaid expenses	4,783,971	78,768
Other receivables	61,273	37,571
Total Current Assets	5,093,422	132,160
Subscription option asset (Note 3)	100,000	-
Copyrights (Note 6)	865,000	865,000
Equipment, net	99,683	166,110
<b>TOTAL ASSETS</b>	<b>\$6,158,105</b>	<b>\$1,163,270</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)</b>		
Current Liabilities:		
Accrued liabilities-other	\$949,907	\$1,253,283
Accrued officers' salaries (Note 7)	85,000	175,000
Acquisition cost payable (Note 6)	36,665	56,502
Current portion of obligations under capital leases (Note 7)	131,005	94,377
Loan payable (Note 8)	139,642	-
Convertible promissory note (Note 9)	167,816	-
Short term loans payable (Note 10)	62,950	-
Total Current Liabilities	1,572,985	1,579,162
Obligations Under Capital Leases (Note 7)	-	83,179
Deposit for shares to be issued	151,592	394,474
<b>TOTAL LIABILITIES</b>	<b>1,724,577</b>	<b>2,056,815</b>
Commitments and Contingencies (Note 7)		
Going Concern (Note 1)		
Related Party Transactions (Note 5)		
Stockholders' Equity (Deficiency) (Note 3)		
Preferred stock, \$0.00001 par value, 100,000,000 shares authorized, none issued and outstanding	-	-
Common stock, \$0.00001 par value, 500,000,000 (December 31, 2011 – 500,000,000) shares authorized, 274,089,203 and 113,072,632 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively.	2,741	1,131

Edgar Filing: Kallo Inc. - Form 10-Q

Additional paid-in capital	15,901,756	8,862,522
Deficit accumulated during the development stage	(11,470,969)	(9,757,198)
Total Stockholders' Equity (Deficiency)	4,433,528	(893,545 )
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$6,158,105	\$1,163,270

See accompanying notes to the unaudited condensed consolidated financial statements

F-1

-3-

---

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Condensed Consolidated Statements of Operations and Comprehensive Loss  
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,		December 12, 2006 (inception) to September 30, 2012
	2012	2011	2012	2011	2012
Revenue	\$ -	\$ -	\$ -	\$ -	\$ 15,887
Cost of Revenue	-	-	-	-	12,840
Gross Profit	-	-	-	-	3,047
<b>Expenses</b>					
General and administration	448,873	3,123,647	1,223,713	3,841,865	9,407,182
Selling and marketing	103,003	39,645	225,341	307,474	744,198
Software development costs	-	70,010	-	539,815	824,292
Foreign exchange loss (gain)	(3,057)	(17,668)	18,349	(4,301)	(6,335)
Depreciation	22,143	21,825	66,427	63,117	173,738
Interest and financing costs	23,429	23,096	62,125	53,790	206,595
Derivative loss	146,064	-	203,868	-	203,868
Change in fair value on convertible promissory note	(81,482)	18,000	(86,052)	18,000	(86,052)
Loss on disposal of equipment	-	-	-	-	6,530
	658,973	3,278,555	1,713,771	4,819,760	11,474,016
Net Loss and Comprehensive Loss	\$ (658,973)	\$ (3,278,555)	\$ (1,713,771)	\$ (4,819,760)	\$ (11,470,969)
<b>Basic and diluted net loss per share</b>					
	\$ (0.004)	\$ (0.067)	\$ (0.012)	\$ (0.107)	
<b>Weighted average shares used in calculating</b>					
	162,520,412	49,204,004	143,088,266	44,942,064	

Basic and diluted net  
loss per share

See accompanying notes to the unaudited condensed consolidated financial statements

F-2

-4-

---



KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency)  
For the period from December 12, 2006 (inception) through to September 30, 2012

	Preferred Stock \$.00001 par value		Common Stock \$.00001 par value		Additional Paid-In Capital	Deficit Accumulated	
	Shares	Amount	Shares	Amount		During the Development Stage	Total Stockholders' Equity (Deficiency)
Balance December 12, 2006 (Inception)	-	\$ -	-	\$ -	\$ -	-	\$ -
Issuance of common shares	-	-	15,000,000	150	(100)	-	50
Net loss	-	-	-	-	-	(18,500)	(18,500)
Balance December 31, 2006	-	-	15,000,000	150	(100)	(18,500)	(18,450)
Issuance of common shares	-	-	1,721,502	17	172,608	-	172,625
Net loss	-	-	-	-	-	(232,602)	(232,602)
Balance December 31, 2007 (Audited)	-	-	16,721,502	167	172,508	(251,102)	(78,427)
Net loss	-	-	-	-	-	(65,770)	(65,770)
Balance December 31, 2008 (Audited)	-	-	16,721,502	167	172,508	(316,872)	(144,197)
Shares issued for Rophe Acquisition	-	-	6,000,000	60	765,240	-	765,300
Issuance of common shares	-	-	150,000	2	14,998	-	15,000
Stock based compensation	-	-	-	-	7,500	-	7,500
Net Loss	-	-	-	-	-	(440,374)	(440,374)

Edgar Filing: Kallo Inc. - Form 10-Q

Balance December 31, 2009 (Audited)	-	-	22,871,502	229	960,246	(757,246)	203,229
Issuance of common shares	-	-	1,133,664	12	170,038	-	170,050
Issuance of units, consisting of common shares and common share warrants	-	-	1,580,000	16	394,984	-	395,000
Shares issued to officers and directors	-	-	13,500,000	135	3,374,865	-	3,375,000
Net Loss	-	-	-	-	-	(3,662,252)	(3,662,252)
Balance December 31, 2010 (Audited)	-	\$ -	39,085,166	\$ 392	\$ 4,900,133	\$ (4,419,498)	\$ 481,027
Issuance of common shares	-	-	13,604,132	136	718,558	-	718,694
Shares issued to officers, directors, employees and others	-	-	58,500,000	585	3,124,415	-	3,125,000
Shares issued for repayment of consulting fees	-	-	1,000,000	10	69,990	-	70,000
Settlement of accounts payable by common shares	-	-	883,334	8	49,426	-	49,434
Net Loss	-	-	-	-	-	(5,337,700)	(5,337,700)
Balance December 31, 2011 (Audited)	-	\$ -	113,072,632	\$ 1,131	\$ 8,862,522	\$ (9,757,198)	\$ (893,545)
Issuance of common shares	-	-	35,832,076	358	1,791,246	-	1,791,604
Shares issued to employees and others for services	-	-	116,834,495	1,168	4,677,645	-	4,678,813
Shares issued for repayment of	-	-	5,000,000	50	349,950	-	350,000

Edgar Filing: Kallo Inc. - Form 10-Q

consulting fees							
Settlement of accounts payable by common shares	-	-	850,000	9	60,418	-	60,427
Settlement of compensation to past officer	-	-	500,000	5	59,995	-	60,000
Commitment shares held in trust by Kodiak (Note 3 & 11)	-	-	2,000,000	20	99,980	-	100,000
Net Loss	-	-	-	-	-	(1,713,771)	(1,713,771)
Balance September 30, 2012 (Unaudited)	\$	274,089,203	\$ 2,741	\$ 15,901,756	\$ (11,470,969)	\$ 4,433,528	

See accompanying notes to the unaudited condensed consolidated financial statements

F-3

-5-

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Condensed Consolidated Statements of Cash Flows  
(Unaudited)

	Nine Months Ended September 30,		December 12, 2006 (inception) to September 30, 2012
	2012	2011	
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Net Loss	\$ (1,713,771)	\$ (4,819,760)	\$ (11,470,969)
Adjustment to reconcile net loss to cash used in operating activities:			
Depreciation	66,427	63,117	173,738
Stock based compensation	47,988	2,769,510	5,943,515
Write-off of deferred financing costs	-	-	66,064
Extinguishment loss on revision of terms of loan conversion into shares	-	-	37,404
Loss on disposal of equipment	-	-	6,530
Non-cash interest accrued	12,150	5,927	15,486
Non-cash derivative loss	203,868	-	203,868
Change in fair value on convertible promissory note	(86,052)	18,000	(86,052)
Non-cash settlement of expenses	415,181	394,905	428,414
Changes in operating assets and liabilities:			
Increase in other receivables	(23,702)	-	(61,273)
Increase in prepaid expenses	(91,123)	-	(113,124)
Increase/(Decrease) in accrued liabilities and officers' salaries	(184,450)	855,935	1,672,910
<b>NET CASH USED IN OPERATING ACTIVITIES</b>	<b>(1,353,484)</b>	<b>(712,366)</b>	<b>(3,183,489)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Cash acquired in Rophe acquisition	-	-	300
Purchase of equipment	-	-	(14,418)
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>-</b>	<b>-</b>	<b>(14,118)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Stockholder advances/(repayments)	-	24,350	41,957
Proceeds from sale of common stock, net	1,397,130	590	2,913,870
Proceeds for shares to be issued	151,592	-	546,066
Deferred financing costs	-	-	(26,064)

Repayment of obligations under capital leases	(53,375)	(30,154)	(162,538)
Proceeds from convertible promissory note	50,000	-	50,000
Proceeds from loans payable	40,494	663,202	82,494
<b>NET CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>1,585,841</b>	<b>657,988</b>	<b>3,445,785</b>
<b>NET (DECREASE) INCREASE IN CASH</b>	<b>232,357</b>	<b>(54,378)</b>	<b>248,178</b>
<b>CASH - BEGINNING OF PERIOD</b>	<b>15,821</b>	<b>59,169</b>	<b>-</b>
<b>CASH - END OF PERIOD</b>	<b>\$ 248,178</b>	<b>\$ 4,791</b>	<b>\$ 248,178</b>
<b>SUPPLEMENTAL CASH FLOW INFORMATION</b>			
Interest paid	\$ -	\$ 40,570	
<b>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES</b>			
Accounts payable as partial consideration for Rophe acquisition	\$ -	\$ -	\$ 100,000
Common stock issued as partial consideration for Rophe acquisition	\$ -	\$ -	\$ 765,300
Acquisition of equipment under capital lease obligations	\$ -	\$ 39,778	\$ 265,706
Conversion of loans payable	\$ -	\$ 698,071	\$ 680,207
Settlement of accounts payable by common shares	\$ 60,427	\$ 40,000	\$ 60,427

See accompanying notes to the unaudited condensed consolidated financial statements

F-4

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Notes to Condensed Consolidated Financial Statements  
September 30, 2012  
(unaudited)

NOTE 1 – ORGANIZATION AND GOING CONCERN

Organization

Kallo Inc. (the “Company” or “Kallo”), formerly, Diamond Technologies, Inc., a development stage company, was incorporated in Nevada on December 12, 2006. The Company originally offered media, inks, printing, and graphic design services to the large format digital printing industry. The Company’s fiscal year ends on December 31st. On December 31, 2009, Kallo entered into an agreement with Rophe Medical Technologies Inc. and its shareholders (collectively “Rophe”) wherein Kallo acquired all of the issued and outstanding shares of common stock of Rophe. As a result of the Rophe transaction, Kallo changed its business focus from selling printing equipment to manufacturing and developing software designed to taking medical information from many sources, and then depositing it into a single source as an electronic medical record for each patient. On January 14, 2011, Kallo Inc. was incorporated in Nevada and merged into Diamond Technologies Inc., at which point the Company changed its name to Kallo Inc.

On December 10, 2010, the Company entered into a North American Authorized Agency Agreement (the “Agreement”) with Advanced Software Technologies, Inc., located in the Grand Cayman Islands (“AST”). Under the Agreement, the Company was appointed sales agent for AST and will be paid fees by AST for selling AST products. The Company has agreed to pay AST a total of \$213,000 for modification of the AST products to comply with the requirements of the Canadian Electronic Health Record market. The AST technology is being incorporated into the Company’s medical information software currently in development.

Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experience of defaults in paying capital leases and loans payable and has incurred operating losses since inception and has an accumulated deficit of \$11,470,969 at September 30, 2012. The Company will continue to incur losses as it develops its products and marketing channels during 2012. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company has met its historical working capital requirements from the sale of common shares and loans from an officer/stockholder. In order to not burden the Company, the officer/stockholder has agreed to provide funding to the Company to pay its annual audit fees, filing costs and legal fees as long as the board of directors deems it necessary. However, there can be no assurance that such financial support shall be ongoing or available on terms or conditions acceptable to the Company.

NOTE 2 – ACCOUNTING POLICIES AND OPERATIONS

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X related to smaller reporting companies. These unaudited condensed consolidated financial statements should be read in conjunction with the annual audited financial statements and notes, which are included as part of the Company's Form 10-K filed with the SEC for the year ended December 31, 2011.

Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. Notes to the financial statements which substantially duplicate the disclosure contained in the audited financial statements for fiscal year ended December 31, 2011 as reported in the 10-K have been omitted. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements.

F-5

-7-

---

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Notes to Condensed Consolidated Financial Statements  
September 30, 2012  
(unaudited)

NOTE 2 – ACCOUNTING POLICIES AND OPERATIONS (continued)

Convertible promissory note

Convertible promissory note is accounted for under FASB Codification ASC 815-15-25-4 (formerly SFAS 155). In accordance with ASC 815-15, the Company performs a fair value re-measurement for any hybrid financial instrument that contains an embedded derivative that otherwise would require bifurcation. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.

Recently Adopted Accounting Pronouncements

In May 2011, the FASB issued ASU 2011-04, “Fair Value Measurement (Topic 820), Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS”. The amendment results in a consistent definition of fair value and ensures the fair value measurement and disclosure requirements are similar between GAAP and International Financial Reporting Standards (“IFRS”). This amendment changes certain fair value measurement principles and enhances the disclosure requirements particularly for Level 3 fair value measurements. This amendment will be effective for the Company on January 1, 2012. We adopted the amendments on January 1, 2012 on a prospective basis. The adoption of ASU No. 2011-04 had no material effect on our financial statements.

In June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-05, Presentation of Comprehensive Income, which revises the manner in which entities present comprehensive income in their financial statements. The ASU removes the presentation options in Accounting Standard Codification Topic 220 and requires entities to report components of comprehensive income in either 1) a continuous statement of comprehensive income or 2) two separate but consecutive statements. In December 2011, FASB issued Accounting Standards Update (“ASU”) No. 2011-12, “Comprehensive Income” which effectively defers the changes in ASU No. 2011-05, “Presentation of Comprehensive Income” that relate to the presentation of reclassification adjustments out of accumulated other comprehensive income to the first quarter of 2012 for the Company. We adopted the amendments on January 1, 2012 and presented a continuous statement of comprehensive loss.

Recent Accounting Pronouncements

In December 2011, the FASB issued ASU 2011-11, “Balance Sheet (Topic 210), Disclosures about Offsetting Assets and Liabilities”. The guidance in this update requires the Company to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. The pronouncement is effective for fiscal years and interim periods beginning on or after January 1, 2013 with retrospective application for all comparative periods presented. The Company’s adoption of the new standard is not expected to have a material effect on the Company’s consolidated financial position or results of operations.

In July 2012, the FASB issued ASU 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment”, which provides companies with the option to first assess qualitative factors in determining whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after



assessing the totality of events and circumstances, an entity concludes that it is not more likely than not that an indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value. Previously, companies were required to perform the quantitative impairment test at least annually. The new accounting guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. We do not anticipate the adoption of the new accounting guidance to have a significant effect on our financial condition or results of operations.

F-6

-8-

---

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Notes to Condensed Consolidated Financial Statements  
September 30, 2012  
(unaudited)

NOTE 3 – STOCKHOLDERS’ EQUITY

Common Stock

On February 1, 2012, the Company issued 1,193,381 restricted shares of common stock to creditors in consideration of satisfaction for services rendered during the period.

On February 29, 2012, the Company’s board of directors approved the issuance of 23,016,963 unregistered shares of common stock to 15 individuals in consideration of \$1,150,848, of which \$394,474 was received as at December 31, 2011.

During the quarter ended March 31, 2012, the Company issued 5,000,000 shares of its common stock valued at \$350,000 to consultants for the provision of various services to the Company.

On February 3, 2012, the Company issued 500,000 shares of its common stock to creditors in consideration of satisfaction of \$35,927 in outstanding payables.

On June 1, 2012, the Company issued 500,000 restricted shares of its common stock to a past officer as compensation of \$60,000 for past services rendered.

During the quarter ended September 30, 2012, the Company issued 12,815,113 shares of its common stock for cash proceeds of \$640,756.

On July 20, 2012, the Company issued 350,000 restricted shares of common stock to a creditor in consideration of satisfaction for services rendered for a fair value of \$24,500.

On September 18, 2012, the Company sold 115,641,114 restricted shares of its common stock at \$0.0001 to various officers and parties related to them in consideration of satisfaction of \$11,564 in outstanding payables and as compensation for future services in the amount of \$4,614,080. Because the sale price was below the quoted stock price per share of \$0.04 per share at the time, the Company considered \$4,614,080 as prepaid compensation which will be recognized as an expense over the lock up period of the restricted shares until August 31, 2013.

On September 26, 2012, the Company entered into an investment agreement with Kodiak Capital Group, LLC (“Kodiak”) whereby the company issued 2,000,000 shares of its common stock in exchange for an option to sell up to \$2,000,000 worth of shares of the Company at a price formula based upon the preceding five days Volume Weighted Average Price at the time of exercise and expires six months from inception. The Company recorded a subscription option asset in the amount of \$100,000 which was determined to be the fair value of the option on September 26, 2012. On October 24, 2012, Kallo filed a prospectus relating to the resale of up to 50,000,000 shares of common stock issuable to Kodiak for investment banking services pursuant to an Investment Agreement dated September 26th, 2012 (See Note 11).

On June 27, 2011, Kallo registered 10,000,000 shares of its Common Stock, par value \$0.00001 per share, under a 2011 Non-Qualified Stock Option Plan (the "2011 Plan"), to be offered and sold to accounts of eligible persons of the Company under the Plan at a proposed maximum offering price per share of \$0.15. This 2011 Plan is for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, consultant or advisor, is intended to advance the best interests of the Company by providing additional incentive to those persons who have a substantial responsibility for its management, affairs, and growth by increasing their proprietary interest in the success of the Company, thereby encouraging them to maintain their relationships with the Company. As at September 30, 2012, 7,233,334 shares have been issued under this 2011 Non-Qualified Stock Option Plan.

F-7

-9-

---

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Notes to Condensed Consolidated Financial Statements  
September 30, 2012  
(unaudited)

## NOTE 3 – STOCKHOLDERS’ EQUITY (continued)

On September 6, 2012, Kallo registered 50,000,000 shares of its Common Stock, par value \$0.00001 per share, under a 2012 Non-Qualified Stock Option Plan (the “2012 Plan”) to be offered and sold to accounts of eligible persons of the Company under the Plan at a proposed maximum offering price per share of \$0.04. This 2012 Plan is for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, consultant or advisor, is intended to advance the best interests of the Company by providing additional incentive to those persons who have a substantial responsibility for its management, affairs, and growth by increasing their proprietary interest in the success of the Company, thereby encouraging them to maintain their relationships with the Company. As at September 30, 2012, no shares have been issued under this 2012 Non-Qualified Stock Option Plan.

## NOTE 4 – WARRANTS

Warrant activity for the year ended December 31, 2011 and the nine months ended September 30, 2012 is as follows:

	Number of Warrants	Weighted Average Exercise Price
Balance, December 31, 2010	1,580,000	\$ 0.50
Granted	-	-
Cancelled	-	-
Exercised	-	-
Balance, December 31, 2011 (audited) and September 30, 2012 (unaudited)	1,580,000	\$ 0.50

Each warrant is exercisable for a period of one year from the effective date of a registration statement filed with the SEC. Such registration statement has not been filed yet.

The value of the stock purchase warrants granted in 2010 was valued at \$117,620 using the following assumptions and estimates in the Black-Scholes model: Expected life of 1.2 years, volatility of 100%, dividend yield of 0% and risk-free interest rate of 1.40%.

## NOTE 5 – RELATED PARTY TRANSACTIONS

Included in the issuance of 23,016,963 unregistered shares of common stock to 15 individuals in consideration of \$1,150,848 on February 29, 2012 were 3,000,000 shares issued to a director of the Company for an amount of \$150,000.

On September 18, 2012, the Company issued 115,641,114 shares of its common stock for consideration of \$11,564 to certain officers and parties related to them and as compensation for future services in the amount of \$4,614,080 (Note

3).

Included in short term loans payable is an amount due to a shareholder and officer of the Company for the amount of \$9,856 (See Note 10) and in accrued liabilities – other is an amount of \$21,743 due to the same person.

Transactions with related parties are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

F-8

-10-

---

KALLO INC.  
(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Notes to Condensed Consolidated Financial Statements  
September 30, 2012  
unaudited

## NOTE 6 – ROPHE ACQUISITION

On December 11, 2009, an agreement was entered into by the Company to acquire 100% of the issued and outstanding shares of Rophe Medical Technologies Inc. (“Rophe”) for cash consideration of \$1,200,000 and 3,000,000 of the Company’s common shares valued at \$0.122 per share for total purchase price of \$1,565,000 (the “Rophe Acquisition”). The \$1,200,000 was initially payable as follows: \$50,000 within 30 days of the date of the agreement; \$200,000 on March 31, 2010; \$250,000 on April 30, 2010; \$233,333 on launch of Project 1; \$233,333 on launch of Project 2; and, \$233,334 on launch of Project 3. This transaction was closed on December 31, 2009.

Subsequently, the Rophe Acquisition payment terms were amended and 3,000,000 additional shares of restricted common stock were issued in 2009 as payment for \$400,000 with the remaining cash consideration as follows: \$35,000 by March 5, 2010, \$65,000 by March 31, 2010, \$233,333 on launch of Project 1; \$233,333 on launch of Project 2; and, \$233,334 on launch of Project 3. As at September 30, 2012, there is a payable in the amount of \$36,665. The 3,000,000 shares were considered issued as at the closing date of the acquisition and the total of 6,000,000 shares issued for the Rophe acquisition are restricted.

The total recorded acquisition price of \$865,000 was allocated to the copyrights obtained in the acquisition as they were the only significant assets of Rophe, which did not have any operations. The Company has not recorded the remaining contingent payment of \$700,000 due to the uncertainty of the launch of Projects 1, 2 and 3.

## NOTE 7 – COMMITMENTS &amp; CONTINGENCIES

## Commitments

## Operating lease

The Company leases office facilities under non-cancelable operating leases. The Company’s obligations under non-cancelable lease commitments are as follows:

Year ending December 31, 2012	\$	12,376
Total	\$	12,376

## Capital lease

Minimum lease payments on capital lease obligations are as follows:

Within one year	\$	131,005
	\$	131,005

## Software development

As discussed in Note 1, the Company has agreed to pay AST a total of \$213,000 for modification of the AST products to comply with the requirements of the Canadian Electronic Health Record market, of which \$24,000 (2011 - \$104,504) was paid in 2012. The remaining balance of \$56,496 is due in 2012.

#### Contingencies

- (a) On July 29, 2011, Watt International Inc. (“Watt”) commenced a third party claim against Kallo concerning monies that Kallo allegedly owed to Watt for branding and internet services provided by Watt to Kallo. Watt is seeking damages in the amount of \$161,673.67 plus unspecified “special” damage. Management is of the opinion that Watt has charged Kallo for services that Watt did not perform, and that Watt has duplicated charges for work that it performed and intends to defend itself vigorously in the suit. Management has recognized an accrual for the amount of the claim.

F-9

KALLO INC.  
 (formerly Diamond Technologies, Inc.)  
 (A Development Stage Company)  
 Notes to Condensed Consolidated Financial Statements  
 September 30, 2012  
 unaudited

NOTE 7 – COMMITMENTS & CONTINGENCIES (continued)

Contingencies (continued)

- (b) The Company has calculated the estimated amount of withholding taxes on stock-based compensation based on valuation obtained from a third party. Should the amount payable be different from the estimated amount, the difference will be recorded in the period of payment.
- (c) Included in accrued officers' salaries is an amount of \$65,000 payable to a past officer for settlement of claims which the Company has agreed to pay in 6 installments of \$10,000 for the months of October 2012 to March 2013 and a final payment of \$5,000 by April 30, 2013. This settlement agreement was a result of an action by the past officer against the Company to recover past compensation due. The Company and the past officer had agreed to settle all the claims in exchange of the Company paying a total of \$130,000 (of which \$65,000 has been paid by September 30, 2012) and issuing 500,000 restricted shares of its common stock to the past officer. In the event the Company fails to make payment of any of the above installments on time and within 10 business days of the past officer giving written notice to the Company of such failure to make payment, the past officer may declare all unpaid installments as immediately due and payable by written notice to the Company.

NOTE 8 – LOAN PAYABLE

As at September 30, 2012, a loan payable of \$139,642 bears interest at 6% per annum, is unsecured and is payable in monthly installments of principal and interest in the amount of Canadian \$7,232.50. Future scheduled repayments of principal are as follows:

Within one year	\$	139,642
	\$	139,642

NOTE 9 – CONVERTIBLE PROMISSORY NOTE

The convertible promissory notes are unsecured and bear interest at 3.25% per annum with all principal and accrued interest due and payable one year from the dates of execution of the Notes. The Notes are due as follows: \$20,000 on April 23, 2013, \$10,000 on July 5, 2013, \$20,000 on August 22, 2012. The Holders may, in lieu of payment of the principal and interest, elect to convert such amount into common shares of the Company at the conversion price per share equal to 30% discount to the average of the previous three lowest trading days over the last 10 trading days prior to the Conversion Date. All shares converted on or after six months from the dates of execution of the notes shall be issued as free-trading, unrestricted shares. The Company may prepay these Notes at anytime without penalty and without the prior consent of the Holders.

At the commitment date, the convertible promissory notes were re-measured and adjusted to their fair values by comparing the effective conversion price to the fair value of the Company's stock. The Company recognized an initial derivative loss of \$203,868 related to the debts on inception dates and recognized a gain of \$86,668 related to change



in fair values on the debts since their inception dates to the period ended September 30, 2012. The number of common shares indexed to the derivative financial instruments used in the above calculation were 2,472,089 and 5,555,555 as at inception date and September 30, 2012 respectively.

Cash received from convertible promissory notes	\$	50,000
Derivative loss on inception date		203,868
Fair value of convertible promissory notes on inception date		253,868
Change in fair value		(86,052)
Fair value as at September 30, 2012	\$	167,816

F-10

KALLO INC.

(formerly Diamond Technologies, Inc.)  
(A Development Stage Company)  
Notes to Condensed Consolidated Financial Statements  
September 30, 2012  
(unaudited)

NOTE 10 – SHORT TERM LOANS PAYABLE

On July 9, 2012, the Company issued a promissory note to a director agreeing to pay the principal amount of \$30,000 plus interest at the rate of 6% per annum on July 31, 2012. Kallo did not pay on the due date and the director advanced a further \$5,000 which is non-interest bearing, unsecured and has no fixed repayment date. The total amount of \$36,868 remains outstanding as at September 30, 2012.

An officer and a stockholder have agreed to provide short term funding to the Company by paying some of its expenses. The advances are non-interest bearing, unsecured and have no fixed repayment dates. As at September 30, 2012, \$26,082 was owing to the officer and the stockholder.

NOTE 11 – SUBSEQUENT EVENT

Resale of shares

On October 24, 2012, Kallo filed a prospectus relating to the resale of up to 50,000,000 shares of common stock issuable to Kodiak for investment banking services pursuant to an Investment Agreement dated September 26th, 2012 (the “Investment Agreement” or “Equity Line of Credit”).

Pursuant to the Investment Agreement, Kallo has the right to “put” to Kodiak (the “Put Right”) up to \$2 million in shares of its common stock (i.e., Kallo can compel Kodiak to purchase its common stock at a pre-determined formula).

The Investment Agreement provides, in part, that following notice to Kodiak, Kallo may put to Kodiak up to \$2,000,000 in shares of its common stock for a purchase price equal to 80% of the Volume Weighted Average Price which is defined as the lowest closing “best bid” price (the highest posted bid price) of the common stock during the five consecutive trading days immediately following the date of our notice to Kodiak of our election to put shares pursuant to the Investment Agreement. Kodiak has indicated that it will resell those shares in the open market, resell our shares to other investors through negotiated transactions, or hold our shares in its portfolio.

The Investment Agreement will terminate when any of the following events occur:

- Kodiak has purchased an aggregate of \$2,000,000 of Kallo common stock or six (6) months after the effective date;
- Kallo file or otherwise enter an order for relief in bankruptcy; or
- Kallo common stock ceases to be registered under the Securities Exchange Act of 1934 (the “Exchange Act”).

Operating lease commitment

On October 12, 2012, the Company renewed the lease of its office facilities for a period of six months starting on December 1, 2012. The Company’s additional obligation under this non-cancelable lease commitments is Canadian \$37,962.

NOTE 12 – COMPARATIVES

The consolidated financial statements have been reclassified, where applicable, to conform to the presentation used in the current period.

F-11

-13-

---

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

There is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay out our bills. This is because we have not generated substantial revenues and do not anticipate generating on-going revenue until we complete the development of our website and engage suppliers and customers to buy our products.

### Plan of Operation

The following Plan of Operation contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth elsewhere in this document.

We are a Medical information company that uses technology to assist physicians and healthcare providers to streamline patient information in a coherent and usable manner. Our software is designed to take patient medical information from many sources and deposit it into a single source as electronic medical records (EMR) for each patient. In addition to our EMR product, we have three early stage products for which we plan to evaluate partnership opportunities in order to further develop and commercialize them.

Our plan and focus during the next twelve months include both selling our existing product as well as developing and possibly selling new products. Since changing to our current business, we have not generated any revenues.

### Our Sales and Marketing Strategy for existing developed products

As of the date of this report, we have achieved a EMR milestone for Specialists, by securing an accepted and signed installation order. The installation has been completed in October 2012 and the user training will be completed in November 2012. Our milestones during the next twelve months are:

1 - Developing our sales organization and marketing the third party products along with our software that bring the data from these products into an EMR system in the major metropolitan areas of Canada

2 – Simultaneously with the build-up of our sales organization, we will build a product support team that will provide installation, training and customer support.

3 – Expanding our market from the larger metropolitan areas to the smaller rural and more distant medical facilities.

Within Canada, we will focus on having a direct sales force to market and sell EMR to walk-in clinics/doctor's offices, Independent Diagnostic Centers /Independent Health Facilities and hospitals.

Outside Canada, we may establish commercial partnerships for all of our product candidates in order to accelerate development and marketing in those countries and further broaden our products' commercial potential.

We have successfully launched one of our copyrighted technologies "MOBILE CARE" - Mobile Clinics in November 2011, and have since then received several enquiries for this product from countries in Africa, Vietnam, North West Territories and Northern Ontario in Canada, USA, and the Middle East. Based on the levels of interest from the local Ministries of Health, we have selected companies with business and technical strengths as our local representatives for sales and support in the region. We expect to see sales revenues from Kallo's Mobile Care business unit in the next twelve (12) months.

## Our Development and Commercialization Strategy for new products

We intend to initiate sales of our products in our target commercial areas. Our target commercial areas are hospitals, clinics and doctors' offices. We expect to focus on marketing our current offering as well as completing product development for our product candidates in order to increase our possibilities for current and future revenue generation.

Our forward-looking plan envisions applying our copyrighted design and technology to develop three additional products, to bring to market integrated computer systems that address today's critical health management needs in epidemic control, medical information flow across borders and provision of health care in rural and remote areas.

In addition to our EMR, which is ready for production, we have prioritized the following products for completion of development and are listing them in order of priority.

C&ID-IMS - our Communicable and Infectious Diseases Information Management System technology.

CCG - our Clinical-Care Globalization technology.

We do not at this time have a definitive timetable as to when we will complete these intense development efforts.

We are considered to be in the development stage, as defined under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 915-205. We have been in the development stage since our inception. We have had no substantial recurring source of revenue; we have incurred operating losses since inception and at September 30, 2012 had a working capital deficiency of \$1,263,534 (excluding prepaid expenses).

The development and marketing of new medical software technology is capital intensive. We have funded operations to date either through the sale of our common stock or through advances made by our key shareholders.

We have utilized funds obtained to date for organizational purposes and to commence certain financial transactions. We require additional funding to complete these transactions (including the acquisition of a service-based, valued-business enterprise and related expenses), expand our marketing and sales efforts and increase the Company's revenue base.

## Operating history; need for additional capital

We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a business enterprise.

To become profitable and competitive, we have to locate and negotiate agreements with manufacturers to offer their products for sale to us at pricing that will enable us to establish and sell the products to our clientele.

We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop, or expand our operations. Equity financing could result in additional dilution to existing shareholders.

## Results of operations

### Revenues

We did not generate any revenues during the nine months ended September 30, 2012 or 2011. Since our inception on December 12, 2006 we generated \$15,887 in revenues. The revenues were generated in fiscal year 2007. Since then we have not generated any revenues. We will start generating revenues in November 2012 when we plan to complete the user training for our first installation of EMR for Specialists.

## Expenses

During the three months ended September 30, 2012 we incurred total expenses of \$658,973, including \$231,425 in salaries and compensation, \$22,143 in depreciation, \$151,622 in professional fees, \$103,003 in selling and marketing expenses, \$64,582 in derivative loss and change in fair value of convertible promissory note and \$86,198 as other expenses whereas during the three months ended September 30, 2011 we incurred total expenses of \$3,278,555, including \$127,623 in salaries and compensation, \$2,369,550 in stock based compensation, \$70,010 in software development costs, \$21,825 in depreciation, \$475,680 in professional fees, \$39,645 in selling and marketing expenses and \$174,222 in other expenses. Our professional fees consist of legal, consulting, accounting and auditing fees. The decrease in our total expenses for the three months ended September 30, 2012 from the comparative period is because in the previous period, the Company incurred \$2,369,500 in non-cash stock based compensation and \$70,010 in software development costs compared to NIL for the current three months period. There is also a decrease of \$324,058 in professional fees and \$100,174 in other expenses as we relied more on internal resources. The increase in salaries and compensation, selling and marketing expenses reflect the increase in activities of the Company as we work towards the development and marketing of a new medical software technology.

During the nine months ended September 30, 2012 we incurred total expenses of \$1,713,771, including \$587,293 in salaries and compensation, \$66,427 in depreciation, \$461,692 in professional fees, \$225,341 in selling and marketing expenses, \$117,816 in derivative loss and change in fair value of convertible promissory note and \$255,202 as other expenses whereas during the nine months ended September 30, 2011 we incurred total expenses of \$4,819,760, including \$393,743 in salaries and compensation, \$2,769,510 in stock based compensation, \$140,215 in software development costs, \$63,117 in depreciation, \$752,383 in professional fees, \$307,474 in selling and marketing expenses and \$393,318 in other expenses. Our professional fees consist of legal, consulting, accounting and auditing fees. The decrease in our total expenses for the nine months ended September 30, 2012 from the comparative period is because in the previous period, the Company incurred \$2,369,500 in non-cash stock based compensation and \$140,215 in software development costs compared to NIL for the current nine months period. There is also a decrease of \$290,591 in professional fees and \$150,266 in other expenses as we relied more on internal resources. Otherwise, the general increase in expenses reflects the increase activities of the Company as we work towards the development and marketing of a new medical software technology.

## Net Loss

During the three months ended September 30, 2012 we did not generate any revenues and incurred a net loss of \$658,973 compared to a net loss of \$3,278,555 during the same period in 2011. The main reason is because in the previous period, the Company incurred \$2,369,500 in non-cash stock based compensation by issuing common shares to various officers and employees.

During the nine months ended September 30, 2012 we did not generate any revenues and we incurred a net loss of \$1,713,771, compared to a net loss of \$4,819,760 during the same period in 2011. The main reason is because in the previous period, the Company incurred \$2,369,500 in non-cash stock based compensation by issuing common shares to various officers and employees.

From our inception on December 12, 2006 to September 30, 2012 we incurred a net loss of \$11,470,969, \$9,407,182 of which was general and administration, \$824,292 of which was software development costs, \$744,198 of which was selling and marketing, \$173,738 of which was depreciation, \$206,595 of which was interest and financing costs and \$114,964 of which was other expenses.

From Inception on December 12, 2006 to September 30, 2012



During the year 2007, we incorporated the company, hired the attorney and the auditor and began to negotiate contracts and sell printing related products.

During the year 2008 we continued sourcing products. We did not sell any products or services.

During the year 2009, we did not sell any products or services. We acquired all of the issued and outstanding shares of common stock of Rophe Medical Technologies, Inc.

During the year 2010, we relocated the Company's executive office to Markham, Ontario, changed the Company's name to Kallo Inc., cancelled various employment contracts with previous officers and obtained forgiveness of debt from several directors and officers for compensation and debt owing to them.

Since inception, we sold 5,000,000 pre-dividend shares of common stock to our officers and directors for \$50; issued 490,500 pre-dividend shares of common stock at \$0.25 per share for a total of \$122,625; and issued 83,334 pre-dividend shares of common stock at \$0.60 per share for a total of \$50,000. Those shares were subsequently increased to reflect a 3 for 1 stock dividend declared on February 11, 2008

In 2009, we sold 150,000 shares of common stock to our President for \$15,000. We issued 6,000,000 shares of common stock to Rophe Medical Technologies Inc. and incurred debt of \$100,000 for 300 common shares of Rophe.

In 2010, we sold 1,133,664 shares of common stock at \$0.15 per share for a total of \$170,050 and 1,580,000 units of the Company's common stock and common share warrant at \$0.25 per unit for gross proceeds of \$395,000. Each unit comprised of one common share and one common share warrant. Each common share warrant is exercisable for a period of one year from the effective date of a registration statement filed with the SEC at a price of \$0.50 per share.

On August 18, 2010, we issued 13,500,000 common stock of the Company valued at \$3,375,000 for cash proceeds of \$1,350 to the directors and officers of the Company and stock based compensation of \$3,373,650.

In 2011, we sold 13,604,132 shares of common stock for a total of \$718,694 and issued 883,334 shares of common stock to creditors in satisfaction of \$49,434 in outstanding payables. We also issued 58,500,000 common stock of the Company valued at \$3,125,000 for cash proceeds of \$5,850 from the directors and officers of the Company and stock based compensation of \$3,119,150.

On October 24, 2011, we issued 1,000,000 common stock of the Company valued at \$70,000 to a consultant for the provision of services relating to the marketing of the Company's business and products to the public.

On February 1, 2012, the Company issued 1,193,381 restricted shares of common stock to creditors in consideration of satisfaction of outstanding debts and of services rendered.

On February 29, 2012, the Company's board of directors approved the issuance of 23,016,963 unregistered shares of common stock to 15 individuals in consideration of \$1,150,848, of which \$394,474 was received as at December 31, 2011.

During the quarter ended March 31, 2012, the Company issued 5,000,000 shares of its common stock valued at \$350,000 to consultants for the provision of various services to the Company.

On February 3, 2012, the Company issued 500,000 shares of its common stock to creditors in consideration of satisfaction of \$25,000 in outstanding payables.

During the quarter ended September 30, 2012, the Company issued 500,000 restricted shares of its common stock to a past officer as compensation for past services rendered.

During the quarter ended September 30, 2012, the Company issued 12,815,113 shares of its common stock for cash proceeds of \$640,756.

On July 20, 2012, the Company issued 350,000 restricted shares of common stock to a creditor in consideration of satisfaction for services rendered for a fair value of \$24,500.

On September 18, 2012, the Company sold 115,641,114 restricted shares of its common stock at \$0.0001 to various

officers and parties related to them in consideration of satisfaction of \$11,564 in outstanding payables and as compensation for future services in the amount of \$4,614,080. Because the sale price was below the quoted stock price per share of \$0.04 per share at the time, the Company considered \$4,614,080 as prepaid compensation which will be recognized as an expense over the lock up period of the restricted shares until August 31, 2013.

On September 26, 2012, the Company entered into a investment agreement with Kodiak Capital Group, LLC (“Kodiak”) whereby the company issued 2,000,000 shares of its common stock in exchange for an option to issue up to sell up to \$2,000,000 at a price formula based upon the preceding five days Volume Weighted Average Price at the time of exercise and expires six months from inception.

### Liquidity and capital resources

As at September 30, 2012, the Company had current assets of \$5,093,422 and current liabilities of \$1,572,985, indicating working capital of \$3,520,437. However, excluding the prepaid expenses of \$4,783,971 which relates mainly to deferred non-cash stock based compensation, there is a working capital deficiency of \$1,363,534. As of September 30, 2012, our total assets were \$6,158,105 in cash, prepaid expenses, copyrights, equipment and our total liabilities were \$1,724,577 comprised of \$949,907 in accrued liabilities, \$85,000 in accrued officer salaries, Rophe Medical Technologies Inc. acquisition costs payable of \$36,665, obligations under capital leases of \$131,005, deposit for shares to be issued of \$151,592, convertible promissory note of \$167,816, short term loans of \$62,950 and loan of \$139,642.

Cash used in operating activities amounted to \$1,353,484 during the nine months ended September 30, 2012, primarily as a result of the net loss adjusted for non-cash items and various changes in operating assets and liabilities.

There were no cash used in investing activities during the current nine months period ended September 30, 2012.

Cash provided by financing activities during the nine months ended September 30, 2012 amounted to \$1,585,841 and represented proceeds from sale of common stock of \$1,397,130, proceeds for shares to be issued of \$151,592, proceeds from convertible promissory note of \$50,000, proceeds from loans payable of \$40,494, net of payments under capital lease obligations of \$53,375.

The Company issued 35,832,976 unregistered shares of common stock for cash consideration of \$1,397,130 during the nine months period, in addition to the \$394,474 which was received as at December 31, 2011.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

### ITEM 4. CONTROLS AND PROCEDURES.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are not effective due to lack of segregation of duties in financial reporting and presence of adjusting journal entries during our last audit. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

On July 29, 2011, Watt International Inc. ("Watt") commenced a third party claim against Kallo concerning monies that Kallo allegedly owed to Watt for branding and internet services provided by Watt to Kallo. Watt is seeking damages

in the amount of \$161,673.67 plus unspecified “special” damage. Management is of the opinion that Watt has charged Kallo for services that Watt did not perform, and that Watt has duplicated charges for work that it performed and intends to defend itself vigorously in the suit. Management has recognized an accrual for the amount of the claim.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

-18-

---

## ITEM 6. EXHIBITS

The following documents are included herein:

Exhibit	Document Description	Incorporated by reference			Filed herewith
		Form	Date	Number	
2.1	Articles of Merger.	8-K	1/21/11	2.1	
3.1	Articles of Incorporation.	SB-2	3/05/07	3.1	
3.2	Bylaws.	SB-2	3/05/07	3.2	
4.1	Specimen Stock Certificate.	SB-2	3/05/07	4.1	
10.1	Option Agreement.	SB-2	3/05/07	10.1	
10.1	Lease Agreement	SB-2	3/05/07	10.1	
10.2	Agreement with Rophe Medical Technologies Inc. dated December 11, 2009.	10-K	3/31/10	10.2	
10.3	Amended Agreement with Rophe Medical Technologies Inc. dated December 18, 2009.	10-K	3/31/10	10.3	
10.4	Amended Agreement with Rophe Medical Technologies Inc. dated March 16, 2010.	10-K	3/31/10	10.4	
10.5	Investment Agreement with Kodiak Capital Group, LLC.	S-1	5/24/10	10.5	
10.6	Registration Rights Agreement with Kodiak Capital Group, LLC.	S-1	10/24/12	10.6	
10.7	Consulting Agreement with Ten Associate LLC.	S-1	5/24/10	10.7	
10.8	Employment Agreement with Leonard Steinmetz.	S-1	5/24/10	10.8	
10.9	Employment Agreement with Samuel Baker.	S-1	5/24/10	10.9	
10.10	Employment Agreement with John Cecil.	S-1	5/24/10	10.10	
10.11	Employment Agreement with Mary Kricfalusi.	S-1	5/24/10	10.11	
10.12	Employment Agreement with Vince Leitao.	S-1	5/24/10	10.12	
10.13	Amended Consulting Agreement with Ten Associate LLC dated October 5, 2010.	8-K	10/14/10	10.13	

Edgar Filing: Kallo Inc. - Form 10-Q

10.14	Agreement with Jarr Capital Corp.	8-K	11/17/10	10.1
10.15	Agreement with Mary Kricfalusi.	8-K	11/19/10	10.1
10.16	Agreement with Herb Adams.	8-K	11/19/10	10.2

-19-

---

Edgar Filing: Kallo Inc. - Form 10-Q

10.18	North American Authorized Agency Agreement with Advanced Software Technologies, Inc.	8-K	12/16/10	10.1	
10.19	Amended Agreement with Jarr Capital Corp.	8-K	2/22/11	10.1	
10.20	Termination of Employment Agreement with John Cecil.	8-K	2/22/11	10.2	
10.21	Termination of Employment Agreement with Vince Leitao.	8-K	2/22/11	10.3	
10.22	Termination of Employment Agreement with Samuel Baker.	8-K	2/22/11	10.4	
10.23	Services Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/2011	10.1	
10.24	Equipment Lease Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/2011	10.2	
10.25	Agreement with Mansfield Communications Inc.	10-K	5/18/2011	10.3	
10.26	Agreement with Watt International Inc.	10-K	5/18/2011	10.4	
10.27	Pilot EMR Agreement with Nexus Health Management Inc.	10-K	5/18/2011	10.5	
14.1	Code of Ethics.	10-K	4/15/08	14.1	
16.1	Letter from Kempisty & Company	8-K	10/27/09	16.1	
16.2	Letter from MaloneBailey, LLP	8-K	3/02/11	16.1	
21.1	List of Subsidiary Companies.	10-K	3/31/10	21.1	
31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
99.1	Audit Committee Charter.	10-K	4/15/08	99.1	
99.2	Disclosure Committee Charter.	10-K	4/15/08	99.2	
101.INS	XBRL Instance Document.				X
101.SCH	XBRL Taxonomy Extension – Schema.				X



Edgar Filing: Kallo Inc. - Form 10-Q

101.CAL	XBRL Taxonomy Extension – Calculations.	X
101.DEF	XBRL Taxonomy Extension – Definitions.	X
101.LAB	XBRL Taxonomy Extension – Labels.	X
101.PRE	XBRL Taxonomy Extension – Presentation.	X

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 14th day of November, 2012.

KALLO INC.  
(The "Registrant")

BY: JOHN CECIL  
JOHN CECIL  
Principal Executive Officer, Principal  
Financial Officer, Principal Accounting Officer,  
and a Chairman of the Board of Directors

BY: VINCE LEITAO  
VINCE LEITAO  
President, Chief Operating Officer and a member  
of the Board of Directors

Exhibit	Document Description	Incorporated by reference			Filed herewith
		Form	Date	Number	
2.1	Articles of Merger.	8-K	1/21/11	2.1	
3.1	Articles of Incorporation.	SB-2	3/05/07	3.1	
3.2	Bylaws.	SB-2	3/05/07	3.2	
4.1	Specimen Stock Certificate.	SB-2	3/05/07	4.1	
10.1	Option Agreement.	SB-2	3/05/07	10.1	
10.1	Lease Agreement	SB-2	3/05/07	10.1	
10.2	Agreement with Rophe Medical Technologies Inc. dated December 11, 2009.	10-K	3/31/10	10.2	
10.3	Amended Agreement with Rophe Medical Technologies Inc. dated December 18, 2009.	10-K	3/31/10	10.3	
10.4	Amended Agreement with Rophe Medical Technologies Inc. dated March 16, 2010.	10-K	3/31/10	10.4	
10.5	Investment Agreement with Kodiak Capital Group, LLC.	S-1	5/24/10	10.5	
10.6	Registration Rights Agreement with Kodiak Capital Group, LLC.	S-1	10/24/12	10.6	
10.7	Consulting Agreement with Ten Associate LLC.	S-1	5/24/10	10.7	
10.8	Employment Agreement with Leonard Steinmetz.	S-1	5/24/10	10.8	
10.9	Employment Agreement with Samuel Baker.	S-1	5/24/10	10.9	
10.10	Employment Agreement with John Cecil.	S-1	5/24/10	10.10	
10.11	Employment Agreement with Mary Kricfalusi.	S-1	5/24/10	10.11	
10.12	Employment Agreement with Vince Leitao.	S-1	5/24/10	10.12	
10.13	Amended Consulting Agreement with Ten Associate LLC dated October 5, 2010.	8-K	10/14/10	10.13	
10.14	Agreement with Jarr Capital Corp.	8-K	11/17/10	10.1	

Edgar Filing: Kallo Inc. - Form 10-Q

10.15	Agreement with Mary Kricfalusi.	8-K	11/19/10	10.1
10.16	Agreement with Herb Adams.	8-K	11/19/10	10.2

Edgar Filing: Kallo Inc. - Form 10-Q

10.18	North American Authorized Agency Agreement with Advanced Software Technologies, Inc.	8-K	12/16/10	10.1	
10.19	Amended Agreement with Jarr Capital Corp.	8-K	2/22/11	10.1	
10.20	Termination of Employment Agreement with John Cecil.	8-K	2/22/11	10.2	
10.21	Termination of Employment Agreement with Vince Leitao.	8-K	2/22/11	10.3	
10.22	Termination of Employment Agreement with Samuel Baker.	8-K	2/22/11	10.4	
10.23	Services Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/2011	10.1	
10.24	Equipment Lease Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/2011	10.2	
10.25	Agreement with Mansfield Communications Inc.	10-K	5/18/2011	10.3	
10.26	Agreement with Watt International Inc.	10-K	5/18/2011	10.4	
10.27	Pilot EMR Agreement with Nexus Health Management Inc.	10-K	5/18/2011	10.5	
14.1	Code of Ethics.	10-K	4/15/08	14.1	
16.1	Letter from Kempisty & Company	8-K	10/27/09	16.1	
16.2	Letter from MaloneBailey, LLP	8-K	3/02/11	16.1	
21.1	List of Subsidiary Companies.	10-K	3/31/10	21.1	
31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
99.1	Audit Committee Charter.	10-K	4/15/08	99.1	
99.2	Disclosure Committee Charter.	10-K	4/15/08	99.2	
101.INS	XBRL Instance Document.				X
101.SCH	XBRL Taxonomy Extension – Schema.				X

101.CAL	XBRL Taxonomy Extension – Calculations.	X
101.DEF	XBRL Taxonomy Extension – Definitions.	X
101.LAB	XBRL Taxonomy Extension – Labels.	X
101.PRE	XBRL Taxonomy Extension – Presentation.	X

